While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19has generated concerns in the early phase of the pandemic because of possible arrhythmogeniceffects in relation to QTc interval prolongation. Indeed, some of these drugs have been historicallyassociated with QT prolongation and Torsade de Point, a potentially lethal ventricular arrhythmia, andtheir first-time use on a very large scale has raised several concerns in the scientific community. Thiswork aims to summarize the underlying arrhythmogenic mechanisms related to the use of potentiallyQT-prolonging drugs used during the pandemic to treat COVID-19.
Schiavone, M., Gasperetti, A., Gherbesi, E., Bergamaschi, L., Arosio, R., Mitacchione, G., et al. (2022). Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19. CARDIAC ELECTROPHYSIOLOGY CLINICS, 14(1), 95-104 [10.1016/j.ccep.2021.10.009].
Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19
Bergamaschi, Luca;
2022
Abstract
While looking for a solution to treat COVID-19, the massive off-label use of several drugs in COVID-19has generated concerns in the early phase of the pandemic because of possible arrhythmogeniceffects in relation to QTc interval prolongation. Indeed, some of these drugs have been historicallyassociated with QT prolongation and Torsade de Point, a potentially lethal ventricular arrhythmia, andtheir first-time use on a very large scale has raised several concerns in the scientific community. Thiswork aims to summarize the underlying arrhythmogenic mechanisms related to the use of potentiallyQT-prolonging drugs used during the pandemic to treat COVID-19.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
